Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Celldex Therapeutics Inc (CLDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CLDX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -34.91% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.12B USD | Price to earnings Ratio - | 1Y Target Price 62.08 |
Price to earnings Ratio - | 1Y Target Price 62.08 | ||
Volume (30-day avg) 765531 | Beta 1.76 | 52 Weeks Range 16.40 - 47.00 | Updated Date 04/1/2025 |
52 Weeks Range 16.40 - 47.00 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4768.26% |
Management Effectiveness
Return on Assets (TTM) -19.38% | Return on Equity (TTM) -26.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 482070493 | Price to Sales(TTM) 159.34 |
Enterprise Value 482070493 | Price to Sales(TTM) 159.34 | ||
Enterprise Value to Revenue 68.67 | Enterprise Value to EBITDA -17.34 | Shares Outstanding 66383800 | Shares Floating 61134843 |
Shares Outstanding 66383800 | Shares Floating 61134843 | ||
Percent Insiders 0.3 | Percent Institutions 112.63 |
Analyst Ratings
Rating 4.58 | Target Price 67.1 | Buy 1 | Strong Buy 9 |
Buy 1 | Strong Buy 9 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Celldex Therapeutics Inc
Company Overview
History and Background
Celldex Therapeutics, founded in 1993, is a biopharmaceutical company focused on developing therapeutic antibodies to treat cancer and other diseases. It initially focused on antibody discovery and development, and has evolved to concentrate on antibody-based therapeutics.
Core Business Areas
- Antibody Therapeutics Development: Focuses on developing monoclonal antibodies and antibody-drug conjugates (ADCs) for cancer treatment. The company's core strategy is to develop targeted therapies that modulate the immune system or directly target cancer cells.
Leadership and Structure
Anthony Marucci is the President and CEO. The company has a board of directors overseeing strategic direction and governance. The organizational structure is typical of a biotech company, with departments for research, development, clinical trials, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Varlilumab: Varlilumab is a CD27 agonist antibody that is being developed for treatment of advanced cancers. It is currently in clinical trials. Varlilumab does not currently have an active market share or revenue generation. Competitors in the cancer immunotherapy space include Roche (RHHBY), Merck (MRK), Bristol Myers Squibb (BMY), and AstraZeneca (AZN).
- CDX-0159: CDX-0159 is an anti-KIT monoclonal antibody designed to selectively bind and inhibit KIT, a receptor tyrosine kinase expressed on mast cells and certain other cell types. It is being developed for chronic spontaneous urticaria and other mast cell-driven diseases and is currently in clinical trials. CDX-0159 does not currently have an active market share or revenue generation. Competitors in mast cell disorders are varied and complex, including companies focused on antihistamines, biologics, and emerging targeted therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense research and development, high regulatory hurdles, and significant competition. The industry is currently focused on targeted therapies and immunotherapies, which represent significant areas of growth.
Positioning
Celldex Therapeutics is positioned as a clinical-stage biopharmaceutical company focused on antibody-based therapeutics. Its competitive advantage lies in its proprietary antibody platform and its focus on developing targeted therapies for cancer and other diseases.
Total Addressable Market (TAM)
The TAM for cancer therapeutics is estimated to be in the hundreds of billions of dollars globally. Celldex Therapeutics is positioned to capture a portion of this TAM by developing novel antibody-based therapies targeting specific cancer pathways. The TAM for mast cell disorders is smaller but still significant, estimated to be in the billions of dollars, and is growing as understanding of mast cell biology increases.
Upturn SWOT Analysis
Strengths
- Proprietary antibody platform
- Strong intellectual property portfolio
- Experienced management team
- Focus on targeted therapies
Weaknesses
- Reliance on clinical trial success
- Limited revenue generation
- High cash burn rate
- Dependence on partnerships for funding
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through acquisitions or in-licensing
- Breakthrough Therapy designation
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from larger pharmaceutical companies
- Patent expirations
Competitors and Market Share
Key Competitors
- RHHBY
- MRK
- BMY
- AZN
Competitive Landscape
Celldex Therapeutics faces significant competition from larger pharmaceutical companies with greater resources. Its competitive advantage lies in its targeted antibody approach and its focus on specific cancer pathways.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Celldex Therapeutics' historical growth is characterized by fluctuations based on clinical trial results and partnership agreements.
Future Projections: Future growth is dependent on the success of its clinical pipeline and the ability to secure additional funding. Analyst estimates vary widely depending on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing Varlilumab and CDX-0159 through clinical trials.
Summary
Celldex Therapeutics is a clinical-stage biotech with potential in antibody therapies but faces substantial risks due to its reliance on clinical trial success. The company's strengths lie in its proprietary platform, but weaknesses include a high cash burn. Positive trial outcomes and strategic partnerships are crucial for its future growth, while competition and regulatory hurdles pose significant threats. Celldex's pipeline has promise, but execution is essential.
Similar Companies
AGEN
Agenus Inc
AGEN
Agenus Inc
XOMA
XOMA Corp
XOMA
XOMA Corp
Sources and Disclaimers
Data Sources:
- Celldex Therapeutics Investor Relations
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Celldex Therapeutics Inc
Exchange NASDAQ | Headquaters Hampton, NJ, United States | ||
IPO Launch date 2008-03-10 | Founder, President, CEO & Director Mr. Anthony S. Marucci M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 186 | Website https://www.celldex.com |
Full time employees 186 | Website https://www.celldex.com | ||
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.